Status:
ACTIVE_NOT_RECRUITING
INTIBIA Pivotal Study
Lead Sponsor:
Coloplast A/S
Conditions:
Urinary Incontinence, Urge
Urinary Bladder, Overactive
Eligibility:
All Genders
22-80 years
Phase:
NA
Brief Summary
Prospective, randomized, double-blind, multicenter study to evaluate the safety and efficacy of an implantable tibial nerve stimulator in subjects with urgency urinary incontinence (UUI).
Detailed Description
All eligible subjects will be implanted with the INTIBIA device. Subjects will be randomized to either INTIBIA therapeutic or INTIBIA non-therapeutic in a 2:1 ratio for the first 3 months of the study...
Eligibility Criteria
Inclusion
- Women or men 22-80 years of age
- Symptoms of overactive bladder with urgency urinary incontinence (UUI) demonstrated on a 72-hour voiding diary defined as a minimum of four (4) leaking episodes associated with urgency, and at least one leaking episode each 24-hour period
- Greater than or equal to 6-month history of UUI diagnosis
- Failure of conservative or behavioral therapy (e.g., bladder diet, timed voiding, bladder training, bladder control strategies, pelvic floor muscle training, fluid management)
- Willing to abstain from OAB medications for the duration of the study
- Willing to maintain a stable dose of all other medications that affect bladder function (e.g., tricyclic antidepressants) for at least four (4) weeks prior to beginning the baseline voiding diary and baseline questionnaires
- Ambulatory and able to use the toilet independently and without difficulty
- Willing and capable of providing informed consent
- Willing and able to complete all procedures and follow-up visits indicated in the protocol
Exclusion
- Diagnosis of stress urinary incontinence or mixed urinary incontinence, as confirmed by cough stress test and with a response of Yes to Q3 on the UDI-6 questionnaire
- Current symptomatic urinary tract infection (UTI), urethritis, or more than three (3) UTIs in past year
- Have post-void residual urine volume \>30% of total voided volume
- Inadequate skin integrity, any evidence of an infection, or lower leg edema limiting placement of device per physician discretion
- Evidence of anatomic abnormalities that could jeopardize the placement of the device or pose a hazard to the subject
- Prior treatment of urinary symptoms with nerve stimulation (e.g., percutaneous tibial nerve stimulation \[PTNS\] or sacral nerve stimulation \[SNS\])
- History of chronic pain (e.g., chronic pelvic pain, fibromyalgia, Lyme disease, chronic back pain)
- An active implantable electronic device regardless of whether stimulation is ON or OFF
- Treatment of urinary symptoms with botulinum toxin therapy within six (6) months
- Any neurological condition that could interfere with normal bladder or tibial nerve function, including debilitating stroke, epilepsy, multiple sclerosis, Parkinson's disease, peripheral neuropathy, fibromyalgia, or spinal cord injury (e.g., paraplegia)
- Current urinary tract mechanical obstruction (e.g., benign prostatic enlargement or urethral stricture)
- Other urinary tract dysfunction (e.g., abnormal upper urinary tract function, vesicoureteral reflux, bladder stone or tumor, urinary fistula)
- End stage renal failure, GFR \< 35, or dialysis
- History of pelvic cancer requiring radiation or chemotherapy treatment within the past two years
- Pelvic organ prolapse at or beyond the hymenal ring
- Interstitial cystitis or bladder pain syndrome as defined by either American Urological Association (AUA) or European Association of Urology (EAU) guidelines prior to INTIBIA implant date
- Diabetes with peripheral nerve compromise or uncontrolled diabetes
- Pregnant as confirmed by urine or serum pregnancy test, plans to become pregnant over the study period, is less than one-year post-partum, is breast-feeding
- Current active or a chronic systemic infection
- Condition requiring magnetic resonance imaging (MRI) of lower leg
- Condition requiring diathermy
- Allergy to polyethylene terephthalate, silicone rubber, platinum, iridium, or polyurethane
- Allergy to local anesthetic or adhesives
- Deemed unsuitable for enrollment by the investigator based on history or physical examination (e.g., bleeding disorders, current anticoagulant medications)
- Enrolled in another investigational or interventional device or drug trial over the study period
Key Trial Info
Start Date :
March 7 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 27 2026
Estimated Enrollment :
208 Patients enrolled
Trial Details
Trial ID
NCT05250908
Start Date
March 7 2022
End Date
June 27 2026
Last Update
May 22 2025
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars-Sinai Medical Group
Beverly Hills, California, United States, 90211
2
Urology Group of Southern California
Los Angeles, California, United States, 90017
3
MedStar Washington Hospital Center
Washington D.C., District of Columbia, United States, 20010
4
Advanced Urology Associates
Daytona Beach, Florida, United States, 32114